Related references
Note: Only part of the references are listed.Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
Jingwei Zhang et al.
SCIENTIFIC REPORTS (2022)
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
Alexey Revenko et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Catherine L. Tan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
Zena N. Willsmore et al.
FRONTIERS IN IMMUNOLOGY (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
Jose M. Gonzalez-Navajas et al.
FRONTIERS IN IMMUNOLOGY (2021)
Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma
Dan Liu et al.
FRONTIERS IN IMMUNOLOGY (2021)
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients
Jing Yang et al.
CANCER CELL INTERNATIONAL (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
Association between local immune cell infiltration, mismatch repair status and systemic inflammatory response in colorectal cancer
Ulf Gunnarsson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Tim-3 finds its place in the cancer immunotherapy landscape
Nandini Acharya et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
FOXP3 in Melanoma with Regression: Between Tumoral Expression and Regulatory T Cell Upregulation
Mirela Cioplea et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Memory CD8+ T cell responses to cancer
Jichang Han et al.
SEMINARS IN IMMUNOLOGY (2020)
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Yoshihiro Ohue et al.
CANCER SCIENCE (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Johannes Griss et al.
NATURE COMMUNICATIONS (2019)
The number and localization of CD68+and CD163+macrophages in different stages of cutaneous melanoma
Satu Salmi et al.
MELANOMA RESEARCH (2019)
Molecular Repolarisation of Tumour-Associated Macrophages
Floris J. van Dalen et al.
MOLECULES (2019)
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Carl Morrison et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer
Shucai Yang et al.
MOLECULAR CANCER (2017)
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Sean P. Arlauckas et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Bin Shang et al.
SCIENTIFIC REPORTS (2015)
High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment
G-F Ma et al.
BRITISH JOURNAL OF CANCER (2014)
FOXP3 inhibits NF-κB activity and hence COX2 expression in gastric cancer cells
Qiang Hao et al.
CELLULAR SIGNALLING (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Somatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate
Lizhong Wang et al.
CANCER CELL (2009)
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells
Lisa M. Ebert et al.
CANCER RESEARCH (2008)
Generation of potent and stable human CD4(+) T regulatory cells by activation-independent expression of FOXP3
Sarah E. Allan et al.
MOLECULAR THERAPY (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer
Sebastian Hinz et al.
CANCER RESEARCH (2007)
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene
Tao Zuo et al.
CELL (2007)
Share Paper
